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An international expert consensus committee recently recommended a brief battery of tests for cognitive
evaluation in multiple sclerosis. The Brief International Cognitive Assessment for MS (BICAMS) battery includes tests
of mental processing speed and memory. Recognizing that resources for validation will vary internationally, the
committee identified validation priorities, to facilitate international acceptance of BICAMS. Practical matters
pertaining to implementation across different languages and countries were discussed. Five steps to achieve
optimal psychometric validation were proposed. In Step 1, test stimuli should be standardized for the target culture
or language under consideration. In Step 2, examiner instructions must be standardized and translated, including all
information from manuals necessary for administration and interpretation. In Step 3, samples of at least 65 healthy
persons should be studied for normalization, matched to patients on demographics such as age, gender and
education. The objective of Step 4 is test-retest reliability, which can be investigated in a small sample of MS and/or
healthy volunteers over 1–3 weeks. Finally, in Step 5, criterion validity should be established by comparing MS and
healthy controls. At this time, preliminary studies are underway in a number of countries as we move forward with
this international assessment tool for cognition in MS.Background
Multiple sclerosis (MS) is an inflammatory disease of the
central nervous system, causing demyelination and neuro-
degeneration in most patients [1,2]. As would be expected
in such a disease with prominent cerebral pathology, a
substantial number [3-5] of MS patients are compromised
neuropsychologically. In recently diagnosed or benign
course patients, the incidence of cognitive impairment
ranges from 20-40% [5,6]. In clinic based samples where
secondary progressive course is more common, roughly
50-60% of patients are affected [4].
Neuropsychological (NP) testing provides quantification
of cognition, and is used clinically to diagnose impairment
and to inform medical and behavioral treatment decisions
[7]. Two descriptors, psychometric or neuropsychological
tests, are often used inter-changeably to describe the cog-
nitive testing procedures used with MS patients [8]. Psy-
chometric tests are standardized, behavioral measures of
mental phenomena. They measure many domains of* Correspondence: benedict@buffalo.edu
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reproduction in any medium, provided the ormental function, including psychomotor speed and dex-
terity, personality or psychopathology [via standardized
questionnaires or surveys], intelligence, memory and other
aspects of cognitive processing [eg attention, language, ex-
ecutive function].
The term neuropsychological test conveys the idea that
the psychometric test result is relevant for conclusions per-
taining to cerebral function. Neuropsychological tests are
used to examine brain-injured patients or to study hypoth-
eses in neuroscience. A deficient neuropsychological test
value is often judged to be indicative of cerebral dysfunc-
tion. The Wechsler Adult Intelligence Scale (WAIS) [9], is
a classic example of a psychometric test of intelligence. It
has carefully standardized instructions, scoring criteria, ex-
tensive age-based normative data, and information derived
from extensive research concerning reliability and validity.
It can also be construed as a neuropsychological test [espe-
cially nonverbal components] because there are extensive
data that show its relationship with cognitive aging, de-
mentia, and other changes in cerebral status.
Psychometric data regarding normal performance, test
reliability and the validity of test interpretation areal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Most tests in common use are carefully standardized
such that the same instructions, stimuli and marking cri-
teria are used by all examiners. Most often, high test-
retest reliability is emphasized in order to avoid error in
repeat testing circumstances. Unfortunately, alternate
test versions and normative data are not available for
some NP tests in all languages and cultures. In addition,
many centers lack expertise in psychometrics and NP
test interpretation.
The Brief International Cognitive Assessment for MS
(BICAMS) initiative was undertaken to recommend a brief,
cognitive assessment for MS that is optimized for small
centers, with perhaps one or few staff members, who may
not have NP training [11]. BICAMS was particularly fo-
cused on international use, to facilitate comparison across
settings. An expert committee of twelve neurologists and
neuropsychologists representing the main cultural groups
that have so far contributed extensive data about cognitive
dysfunction in MS was convened. The opinions generated
from the meeting are published elsewhere [11]. In brief,
the panel recommended one particular test with high reli-
ability and good sensitivity, the Rao [12] adaptation of the
Symbol Digit Modalities Test (SDMT) [13]. Consensus was
also achieved on optimal measures for learning and mem-
ory in MS patients, time permitting: the initial learning
trials of the second edition of the California Verbal Learn-
ing Test (CVLT2) [14] and the revised Brief Visuospatial
Memory Test (BVMTR) [15].
In order to facilitate international implementation of the
BICAMS assessment, multiple translations are needed, asFigure 1 Faux stimuli for Symbol Digit Modalities Test.well as psychometric research to insure the reliability and
validity of new test forms. With this in mind, a second
conference was held to develop consensus on a BICAMS
validation protocol.
Brief International Cognitive Assessment for MS
(BICAMS) description
The SDMT [13] presents a series of nine symbols, each
paired with a single digit in a key at the top of a stand-
ard sheet of paper. An adapted version of the test is pre-
sented in Figure 1. Patients are asked to voice the digit
associated with each symbol as rapidly as possible for
90 sec. There is a single outcome measure – the number
correct over the 90 sec time span.
The auditory/verbal learning test is the CVLT2 [16].
The test begins with the examiner reading a list of 16
words [Figure 2]. Patients listen to the list and report as
many of the items as possible. There is no instruction as
to the order in which items are recalled. After recall is
recorded, the entire list is read again followed by a sec-
ond attempt at recall. Altogether, there are five learning
trials. The reader will note that the 16-item list [see faux
example in Figure 2] has words that conform to four
semantic categories, in this case sports, vegetables,
clothes, and tools. Some subjects will recall items in
a grouped fashion, and others may recall the list in
serial order. There are many variables of recall avail-
able in the CVLT2, as a second list is presented, and
after 25 min there is a delayed recall trial as well as
a yes/no recognition memory task. The BICAMS
panel noted that few studies have shown incremental
Figure 2 Faux stimuli for California Verbal Learning Test Second Edition.
Figure 3 Faux stimuli for Brief Visuospatial Memory Test
Revised.
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recalled items over the five learning trials is most
sensitive [17].
Visual/spatial memory is assessed in BICAMS using the
BVMTR [18]. In this test, six abstract designs [Figure 3]
are presented for 10 sec. The display is removed from view
and patients render the stimuli via pencil on paper manual
responses. Each design receives from 0 to 2 points repre-
senting accuracy and location. Thus, scores range from 0
to 12. There are three learning trials, and the primary out-
come measure is the total number of points earned over
the three learning trials. Because there is little evidence
that the delayed recall trial adds to discriminant validity in
MS [4,19], as in the MATRICS consensus battery [20],
only the initial learning trials are recommended for
BICAMS.
Conference process
Having already decided on the core [SDMT] and ancillary
memory tests [CVLT2, BVMTR], the focus of the confer-
ence was on a BICAMS psychometric validation protocol.
The committee reviewed basic psychometric standards
from the literature [10,21-26] that are widely accepted for
validation of behavioral or psychological outcome mea-
sures. Recognizing that economic resources for validation
will vary across country and region, the committee dis-
cussed priorities for validation, that is, those aspects of re-
search design that would enable empirical appraisal of
core psychometrics that may engender confidence and
wide application of BICAMS. Following consensus on
these central components, it was noted that most of the
psychometric evidence relating to the BICAMS tests relieson US samples and discussion shifted to practical matters
pertaining to implementation across different languages
and countries.
Benedict et al. BMC Neurology 2012, 12:55 Page 4 of 8
http://www.biomedcentral.com/1471-2377/12/55Psychometric standards
Standardization
The first step in the development of any test is to ensure
that test stimuli and administration procedures have good
face validity and consistent stimulus presentation. While
this can be a painstaking process during the initial phases
of psychometric test development, the work is already
done for the tests that were selected for BICAMS. The
SDMT, CVLT2 and BVMTR stimuli are well established
and are readily mass produced using digital and print
technology. Examiners can be easily trained to use stan-
dardized instructions, more or less verbatim, to enhance
reliability across settings. The BICAMS tests are adequate
in this regard.
Normalization of raw scores
Normative data are of course essential for the clinical
application of psychometric, neuropsychological tests.
Acquiring normative data can be an expensive endeavor.
For example, the recently revised US normative data for
BVMTR has a sample size of 588 [27]. These data were
fairly recently acquired and are judged by the BICAMS
committee to be current.
Normalization data for SDMT are more complicated.
The manual based norms date to 1982, raising the spectre
of cohort effects [ie gradual shift upward over time] or
poor generalizablity to patients and controls in the present
day. Benedict et al published normative data on the MAC-
FIMS battery, which includes the SDMT, in 2006 [4] and
2010 [28], using US healthy samples numbering 56 and
120 respectively. These are controlled research studies with
applicability largely restricted to clinicians treating MS
patients. A potential problem is that normative data from
one region [North Eastern USA in this case] may result in
interpretive error when applied to raw test scores derived
from a different culture, language, region or country.
Reliability
By reliability we mean the degree to which there is error
when using the same instrument across settings, exami-
ners, etc. It is perhaps the most critical psychometric cri-
terion - if the test is unreliable, there is little confidence
in the validity of the outcome. Of the various forms of
reliability, the panel decided that test-retest reliability
has the highest priority and is most relevant for future
BICAMS validation. The coefficient of variation can be
used in very small samples to determine the extent to
which changes in mean values outweigh the variance in
test scores [29]. A more valid measure of test-retest reli-
ability is the Pearson correlation coefficient [30]. Most
commonly, a brief test-retest interval ranging from
1–3 weeks is employed. For most purposes, r values for
test-retest correlation are considered adequate if >0.70
and good if >0.80 [23].The SDMT has particularly high test-retest reliability. In
one US study of MS patients the test-retest r value was
0.97. In a US study repeating the test over six monthly ses-
sions, r values approximated 0.80 for healthy controls and
0.90 for MS patients. Acceptable test-retest reliability
[CVLT2=0.78; BVMTR=0.91] was found in a well con-
trolled investigation with US MS patients [31].
Validity
Rather than accuracy, validity refers to the meaning of a
test score. There are multiple aspects of validity in psy-
chometric science. Does a low score, for example, repre-
sent the presence of neuropsychological dysfunction, a
particular disease state such as MS, a high likelihood of
brain atrophy or some other marker of cerebral involve-
ment, or perhaps an increased risk of failing at work?
Correlations between test scores and other measures [ie
validity coefficient r] and comparing differences in the
performance from specified samples [eg, MS vs controls;
employed vs disabled MS patients] are common meth-
ods of investigation.
The BICAMS committee decided that the most import-
ant aspect of validity for clinical purposes is criterion-
related validity, most notably differentiating MS patients
from healthy controls. All of the BICAMS tests discrimin-
ate well with SDMT most often the most sensitive meas-
ure in NP batteries [4,19].
A more difficult endeavor is to establish the ecological
or predictive validity of a psychometric test [32]. Neuro-
psychological testing is correlated with a wide range of
activities of daily living in MS [33-40], as well as work
disability [41-44]. The BICAMS tests are correlated with
vocational outcomes [4,45-47] and recently job loss was
associated with specific decline of 4–5 points on SDMT
[48]. More such research is needed in order to clearly
establish thresholds for clinically meaningful changes for
the BICAMS measures.
Alternate test forms
When NP tests are repeated in healthy volunteers or
stable MS patients, performance often improves for two
reasons: item-specific or task-specific learning [49]. The
former refers to the learning of, or memory for, specific
test stimuli. For example, on the CVLT2, one might re-
member specific words from one testing session to the
next. Indeed, on a similar test, the 1st trial recall was
similar to the delayed recall trial of the same test admi-
nistered two weeks earlier, but only when the same list
was repeated [49]. Test- or task-specific learning refers
to the benefit of performing the same behavioral proced-
ure successively, even if the to-be-remembered stimuli
are altered. For example, one could possibly learn to
label BVMTR figures verbally, a strategy that may carry
over to the next session, despite presenting different
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play a role in retest effects, in MS, we [31] have found
that changing stimuli reduces practice effects on mem-
ory tests such as the CVLT2 and BVMTR.
The SDMT was originally published with one test
form. Alternate forms were generated by Rao and collea-
gues [3,12], but in the only work examining inter-form
equivalence [50], there was little support for the forms
being equivalent. Recently, two new forms were created
and found to be equivalent to the standard form [51].
There are two forms for the CVLT2. In the CVLT2 test
manual, the normative data are very similar for each
form, and the forms yielded similar data in a test-retest
within-subjects design [31]. There is strong support for
inter-form reliability for the BVMTR [20,31,49,52-54].
Consensus opinion: the BICAMS validation
protocol
The above list of psychometric criteria is not intended to
be comprehensive, but the discussed items are essential in
the test development process. As we move forward with
implementing BICAMS internationally, each of these cri-
teria may be difficult to achieve in other languages and cul-
tures. In this section, we describe the suggested, core
validation process, highlighting special considerations for
each of the BICAMS measures.
The BICAMS tests were selected, in part, due to extant
validation findings and thus it is not surprising that they
hold up well to psychometric scrutiny. Table 1 sum-
marizes what we know about the current English versions
of BICAMS. Note that the tests are good on the most pri-
mary criteria, involving standardization, normalization,
test-retest reliability and criterion-related validity. More
variable data are available pertaining to alternate forms
and predicting clinically meaning changes over time.
Looking forward, as summarized in Appendix 1 below,
we envisage five steps in future validation protocols in
populations for whom English is not the first language.
Preliminary work in Step 1 will be needed to maximize
standardization while remaining true to the meaning of
the original version, where possible. The extant SDMT
stimuli are deemed adequate for international use, at least
for cultures where Arabic numerals are in common use.Table 1 Manner in which BICAMS measures meet psychometr
SDMT
Standardization Smith 1982 Teat Manual
Normalization Parmenter 2010. Peer review jou
Reliability I: Test-Retest Benedict 2005 r = 0.91
Reliability II: Alternate Form Rao 1991. Benedict 2012. Good
Validity I: Criterion Related Many Studies. Good
Validity II: Clinically Meaningful Change Morrow 2010. FairOne consideration is the pronounciation of numbers
which may vary from monosyllabic to polysyllabic utter-
ances [eg one in English and nueve in Spanish], or be sim-
ply longer in others [eg üheksa in Estonian]. Rarely, the
meaning of the SDMT and BVMTR symbols could be-
come important. These stimuli have little semantic mean-
ing in English but could conceivably have meaning in
some cultures. Like the SDMT stimuli, the BVMTR test
stimuli are adequate for international application.
The CVLT2 is of course entirely another matter. Here,
precise translation necessitates as close approximation of
the English words as possible, while maintaining word fre-
quency in the target language, semantic relationships among
the target words, orthography, and alike. As noted above, in
some languages this could mean a very arduous process.
The BICAMS committee agreed that in some countries, an-
other, simple, auditory word-list learning test could replace
the CVLT2, provided that the procedure is in the common
format – that is reading the list on each learning trial and
including at least three learning trials. Some English lan-
guage examples are the Rey Auditory Verbal Learning Test
[55] and the revised Hopkins Verbal Learning Test [56,57].
All BICAMS tests must re-standardize the administra-
tion and scoring instructions in the new language. The
time required for Step 2 will depend on the specific test
and technical support available. The patient instructions
for SDMT are brief, and there is minimal instruction ne-
cessary for scoring the test in the standardized manner.
In contrast, the scoring aspects of the BVMTR manual
are quite detailed. Patient responses could be delivered
to another party and scored blindly in lieu of translating
the entire scoring sections of the manual.
In Step 3, a sample of at least 65 healthy volunteers
must be studied with the new BICAMS to develop norma-
tive data in the native language. This minimum sample
size should provide enough power to detect a medium ef-
fect size in a two-group [eg MS vs controls] comparison.
Unless a larger sample is available, the normalization sam-
ple should be group matched to population studies of MS
patients in terms of demographic characteristics. Linear
regression approaches can be employed to extend the ap-
plicability of the data to demographics that are not fully
represented in the database.ic criteria in samples with English as a first language
CVLT2 BVMTR
Delis 2000 Test Manual Benedict 1997 Test Manual
rnal article Delis 2000 Test Manual Benedict 2005 Test Manual
Benedict 2005 r = 0.80 Benedict 2005 r = 0.91
Delis 2000. Fair Benedict 1996. Good
Many Studies. Good Many Studies. Good
No or Little Data No or Little Data
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controls by a repeat testing session 1–3 weeks after baseline
[Step 4]. While both samples are of interest, the panel
believes that reliability in MS is more important than in
healthy volunteers. In order to assess criterion-related valid-
ity [Step 5], the controls must be compared to MS patients,
with control for demographics. If Steps 1 and 2 have been
completed effectively, all BICAMS variables should discrim-
inate the groups significantly, with d values >0.5. Studies to
determine the validity of BICAMS in distinguishing MS
populations from healthy controls will need to be carefully
constructed, because the criteria of diagnosis of MS
adopted may vary among countries [58]. It may be neces-
sary for published data to be segmented to allow compari-
son with MS samples from other language groups and the
BICAMS committee will facilitate this wherever possible.
Finally, other psychometric considerations include
inter-rater reliability, alternate forms, and various forms
of convergent and discriminant validity. These are not
deemed essential, but potentially valuable. For example,
does BICAMS predict vocational outcomes? Are low
BICAMS scores associated with brain atrophy? Alternate
form reliability work has already been commenced by
some members of the BICAMS committee.
Conclusion
The Brief International Cognitive Assessment for MS
(BICAMS) initiative was undertaken to recommend a
brief, cognitive assessment for MS that can be utilized
internationally, in small centers, with perhaps one or few
staff members, who may or may not have formal neuro-
psychological training. Consensus was earlier achieved
regarding the BICAMS tests, with special consideration
for SDMT, and supplementation by CVLT2 and
BVMTR, time permitting. Research is needed to validate
BICAMS where English is not the first language. In this
article, we have summarized a second consensus opinion
which offers a process by which BICAMS can be vali-
dated in other languages. Research projects pursuing
some of the aims described herein are underway.
Appendix 1 Recommended Step-by-Step Protocol
for BICAMS Validation
▪Step 1, Standardization and Translation of Test Stimuli.
For visual stimuli, determine ifthere are any semantic
associations to stimuli in the culture or language under
consideration. For CVLT2 must match new words on
word frequency and appropriate similarity ofmeaning. If
these parameters cannot be applied scientifically, then ex-
pert review andperformance on test by appropriate partici-
pants will be utilized to assess translation.
▪Step 2, Standardization and Translation of Test
Instructions. All information from the testmanual neces-
sary for administration and interpretation must betranslated, back translated,and checked for errors.
Where possible the translated instructions should be
validated againstexpected participant performance in
terms of accuracy and error profile. Step 4 will alsocon-
tribute to the accuracy of the test instructions.
▪Step 3, Normalization. Large samples of 150 or more
healthy persons are needed for dataapplicable to persons
of all ages and diverse ethnicity. The minimum sample
size is 65healthy volunteers, provided they are group
matched on demographics to either a concurrentMS
sample, or matched to samples in other published de-
scriptive MS studies. Wherepossible, the distribution of
test scores and error profile of the normalization sample
shouldbe examined and compared to published distribu-
tions from other language groups.
▪Step 4, Test-Retest Reliability. Assessment of this cri-
terion can be achieved by evaluatingan MS and/or
healthy volunteer sample on two occasions separated by
1–3 weeks. This is thegold standard separation where
the question is only test reliability, controlling for matur-
ationeffects. A Pearson’s correlation coefficient >0.70 will
usually be required.
▪Step 5, Criterion-Related Validity. This step can be
pursued in conjunction with Step 3, inthat an MS sam-
ple can be compared to a healthy control group that also
serves fornormalization. To determine if a new Italian
BVMTR is sensitive to MS disease state, forexample,
compare 50 patients to the healthy controls in Step 3.
After the study, the investigator adds another 35 healthy
volunteers to round out the normalization sample.
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